Topical squalamine under study for treatment of occult lesions

SAN FRANCISCO — The combination of topical squalamine and ranibizumab for treatment of occult lesions less than 10 mm2 in patients with age-related macular degeneration is under study based on trends seen in a subanalysis of the IMPACT study, according to a speaker here.The IMPACT phase 2 study included 128 patients with wet AMD with both classic and occult lesions randomized to receive topical squalamine (Ohr Pharmaceutical) twice daily or placebo drops twice daily, both in combination with monthly injections of ranibizumab (Genentech).